The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Cardiac hypertrophy and histone deacetylase–dependent transcriptional repression mediated by the atypical homeodomain protein Hop
Open accessAbstract
Activation of multiple pathways is associated with cardiac hypertrophy and heart failure. Repression of antihypertrophic pathways has rarely been demonstrated to cause cardiac hypertrophy in vivo. Hop is an unusual homeodomain protein that is expressed by embryonic and postnatal cardiac myocytes. Unlike other homeodomain proteins, Hop does not bind DNA. Rather, it modulates cardiac growth and proliferation by inhibiting the transcriptional activity of serum response factor (SRF) in cardiomyocytes. Here we show that Hop can inhibit SRF-dependent transcriptional activation by recruiting histone deacetylase (HDAC) activity and can form a complex that includes HDAC2. Transgenic mice that overexpress Hop develop severe cardiac hypertrophy, cardiac fibrosis, and premature death. A mutant form of Hop, which does not recruit HDAC activity, does not induce hypertrophy. Treatment of Hop transgenic mice with trichostatin A, an HDAC inhibitor, prevents hypertrophy. In addition, trichostatin A also attenuates hypertrophy induced by infusion of isoproterenol. Thus, chromatin remodeling and repression of otherwise active transcriptional processes can result in hypertrophy and heart failure, and this process can be blocked with chemical HDAC inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Heart Disease: A Textbook of Cardiovascular Medicine.
(1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-3-415_3 · Cited by 4,109
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815
Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities
Braunwald, E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711063371906 · Cited by 1,424
Histone and chromatin cross-talk
Fischle, W., Wang, Y., & Allis, C. D. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00013-9 · Cited by 1,207
The Genetic Basis for Cardiomyopathy
Seidman, J. G., & Seidman, C. (2001) · Cell · doi:10.1016/s0092-8674(01)00242-2 · Cited by 1,046
Cited by
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Linking actin dynamics and gene transcription to drive cellular motile functions
Olson, E. N., & Nordheim, A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2890 · Cited by 958
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice
Callis, T. E., Pandya, K., Seok, H. Y., Tang, R.-H., Tatsuguchi, M., Huang, Z.-P., Chen, J.-F., Deng, Z., Gunn, B., Shumate, J., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36154 · Cited by 861
Hypertrophy of the Heart: A New Therapeutic Target?
Frey, N., Katus, H. A., Olson, E. N., & Hill, J. A. (2004) · Circulation · doi:10.1161/01.cir.0000120390.68287.bb · Cited by 851
The world of protein acetylation
Drazic, A., Myklebust, L. M., Ree, R., & Arnesen, T. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.06.007 · Cited by 804
Tham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., & McMullen, J. R. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1477-x · Cited by 708
Cardiomyocyte Maturation: New Phase in Development
Guo, Y., & Pu, W. T. (2020) · Circulation Research · doi:10.1161/circresaha.119.315862 · Cited by 653
Chang, S., McKinsey, T. A., Zhang, C. L., Richardson, J. A., Hill, J. A., & Olson, E. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8467-8476.2004 · Cited by 613
Actin’ together: serum response factor, its cofactors and the link to signal transduction
Posern, G., & Treisman, R. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.09.008 · Cited by 527
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity
Trivedi, C. M., Luo, Y., Yin, Z., Zhang, M., Zhu, W., Wang, T., Floss, T., Goettlicher, M., Noppinger, P. R., Wurst, W., et al. (2007) · Nature Medicine · doi:10.1038/nm1552 · Cited by 468
Self-citationHDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
Yoon, S., & Eom, G. H. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.1 · Cited by 464
Signaling effectors underlying pathologic growth and remodeling of the heart
van Berlo, J. H., Maillet, M., & Molkentin, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62839 · Cited by 445
Control of Cardiac Growth by Histone Acetylation/Deacetylation
Backs, J., & Olson, E. N. (2006) · Circulation Research · doi:10.1161/01.res.0000197782.21444.8f · Cited by 440
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy
Cao, D. J., Wang, Z. V., Battiprolu, P. K., Jiang, N., Morales, C. R., Kong, Y., Rothermel, B. A., Gillette, T. G., & Hill, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015081108 · Cited by 405
Gentles, A. J. (2010) · JAMA · doi:10.1001/jama.2010.1862 · Cited by 395
Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy
Kong, Y., Tannous, P., Lu, G., Berenji, K., Rothermel, B. A., Olson, E. N., & Hill, J. A. (2006) · Circulation · doi:10.1161/circulationaha.106.625467 · Cited by 377
Kee, H. J., Sohn, I. S., Nam, K. I., Park, J. E., Qian, Y. R., Yin, Z., Ahn, Y., Jeong, M. H., Bang, Y.-J., Kim, N., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.559724 · Cited by 368
Self-citationBecker, H., Marcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., Paschka, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1496 · Cited by 338
MicroRNA-22 Regulates Cardiac Hypertrophy and Remodeling in Response to Stress
Huang, Z.-P., Chen, J., Seok, H. Y., Zhang, Z., Kataoka, M., Hu, X., & Wang, D.-Z. (2013) · Circulation Research · doi:10.1161/circresaha.112.300682 · Cited by 292
Toward transcriptional therapies for the failing heart: chemical screens to modulate genes
McKinsey, T. A., & Olson, E. N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524144 · Cited by 288
Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo
McDonald, O. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26505 · Cited by 284
Regulation of fetal gene expression in heart failure
Dirkx, E., da Costa Martins, P. A., & De Windt, L. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.07.023 · Cited by 283
Signaling and Transcriptional Networks in Heart Development and Regeneration
Bruneau, B. G. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008292 · Cited by 280
Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease
Li, P., Ge, J., & Li, H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0235-9 · Cited by 269
Genetic causes of human heart failure
Morita, H., Seidman, J. G., & Seidman, C. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524351 · Cited by 264
Friedman, C. E., Nguyen, Q., Lukowski, S. W., Helfer, A., Chiu, H. S., Miklas, J., Levy, S., Suo, S., Han, J.-D. J., Osteil, P., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.09.009 · Cited by 258
Zinc binding groups for histone deacetylase inhibitors
Zhang, L., Zhang, J., Jiang, Q., Zhang, L., & Song, W. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1417274 · Cited by 240
Therapeutic potential for HDAC inhibitors in the heart
McKinsey, T. A. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134712 · Cited by 230
Guo, W., Shan, B., Klingsberg, R. C., Qin, X., & Lasky, J. A. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00128.2009 · Cited by 218
Epigenetic regulation: A new frontier for biomedical engineers
Chen, Z., Li, S., Subramaniam, S., Shyy, J. Y.-J., & Chien, S. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044720 · Cited by 163
Sanderson, L., Taylor, G. W., Aboagye, E. O., Alao, J. P., Latigo, J. R., Coombes, R. C., & Vigushin, D. M. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000638 · Cited by 90
Metadata
- Authors
- Kook, H., Lepore, J. J., Gitler, A. D., Lu, M. M., Wing-Man Yung, W., Mackay, J., Zhou, R., Ferrari, V., Gruber, P., & Epstein, J. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-09-15
- Volume
- 112
- Issue
- 6
- Pages
- 863-871
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2114815592
- Cited by
- 332
- References
- 41
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.